Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019.
Lob SH, DePestel DD, DeRyke CA, Kazmierczak KM, Young K, Motyl MR, Sahm DF. Lob SH, et al. Among authors: depestel dd. Open Forum Infect Dis. 2021 Jun 16;8(7):ofab320. doi: 10.1093/ofid/ofab320. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34307727 Free PMC article.
A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals.
Puzniak L, DePestel DD, Srinivasan A, Ye G, Murray J, Merchant S, DeRyke CA, Gupta V. Puzniak L, et al. Among authors: depestel dd. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02564-18. doi: 10.1128/AAC.02564-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30917987 Free PMC article.
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF. Karlowsky JA, et al. Among authors: depestel dd. Clin Infect Dis. 2021 Jun 15;72(12):2112-2120. doi: 10.1093/cid/ciaa381. Clin Infect Dis. 2021. PMID: 32246147
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia.
Shortridge D, Pfaller MA, Arends SJR, Raddatz J, DePestel DD, Flamm RK. Shortridge D, et al. Among authors: depestel dd. Open Forum Infect Dis. 2019 May 20;6(6):ofz240. doi: 10.1093/ofid/ofz240. eCollection 2019 Jun. Open Forum Infect Dis. 2019. PMID: 31263733 Free PMC article.
Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study.
Brown ML, Motsch J, Kaye KS, File TM, Boucher HW, Vendetti N, Aggrey A, Joeng HK, Tipping RW, Du J, DePestel DD, Butterton JR, Paschke A. Brown ML, et al. Among authors: depestel dd. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa054. doi: 10.1093/ofid/ofaa054. eCollection 2020 Mar. Open Forum Infect Dis. 2020. PMID: 32154325 Free PMC article.
51 results